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BACKGROUND: Primary cutaneous melanoma still constitutes the main cause of skin cancer death in developed countries, and 
its incidence in recent years has been increasing in a steady, worrisome manner. 
OBJECTIVES: This study evaluated the clinical, epidemiological and demographic aspects of this disease, and correlated them 
with patient prognosis. 
METHODS: Using epidemiologic and clinical data, we analyzed 84 patients with mild to severe primary cutaneous melanoma 
treated between 1990 and 2007. Slides containing surgical specimens were analyzed, and new slides were made from archived 
paraffin sections when necessary.
RESULTS: The melanoma incidence was higher in areas of sun exposure, with lesions commonly observed in the trunk for males, 
and lower limbs for females. In addition to Breslow’s thickness and ulceration (p = 0.043 and p < 0.001, respectively), the mitotic 
rate per mm2 also correlated with worse patient outcome (p = 0.0007). The sum of ulceration (0 when absent or 1 when present), the 
Breslow index (1 when <1 mm, 2 when >1 mm and <4 mm, 3 when >4 mm) and the mitotic index (0 when absent or 1 when >1 per mm2) 
allowed the establishment of a prognostic score: if the sum was equal to or over three, nearly all (91.7%) patients had systemic disease. The 
5-year survival was approximately seventy percent.
CONCLUSION: Because American Join Committee of Cancer Staging will update the classification of malignant tumors (TNM) 
staging in the near future, and introduce mitosis as a prognostic factor, our results show the importance of such a feature. Additional 
studies are necessary to confirm the importance of a prognostic score as proposed herein.
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INTRODUCTION
Melanoma is a tumor of neuroectodermal origin that 
is formed from melanocytes - cells that are found along 
the basal layer of the epidermis with the main function of 
producing the pigment melanin.1 It has been showing a 
steady, worrisome increase in incidence that is likely due to 
the intermittent habit of sun exposure, which is considered 
to be the major etiologic factor for skin cancer.2
Melanoma is a neoplasm with good prognosis when 
diagnosed early. Nevertheless for intermediate thickness (1 
to 4 mm in depth), it is not possible to predict the disease 
progression, varying from 63 to 89% for 5-year survival. 
However, when deeper than 4 mm, the 5-year survival rates 
are low (33 to 55%).3-5 The transition from radial growth to 
vertical growth grants melanoma with higher aggressiveness, 
the larger and deeper the lesion is.1
Melanoma shows great potential for dissemination, 
which is the reason it constitutes one of the most severe 
tumors among skin lesions, with high mortality rates when 
diagnosed late.6-8
However, even with large tumor resections,9 the 5-year 
survival rates remain low, resulting in the search for new 
treatment methods. Thus, several studies conducted in the 
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1950s and 1960s sought to establish melanoma-related 
predictive factors.
In 1969, Clark et al.10 proposed staging criteria for 
lesions on the basis of skin invasion levels. Subsequently, 
Breslow and Macht 11 evidenced the importance of the 
primary melanoma thickness in millimeters, and this 
index became the most important prognostic indicator,12, 
13 in association with data on ulceration, mitosis and 
regression.5,14,15
Preventive campaigns, dermatoscopy, therapeutic 
approach protocols, determination of anatomic-pathologic 
prognostic factors, and more accurate staging through the 
study of sentinel lymph nodes have allowed for the early 
diagnosis, and treatment of melanomas in the last decade.16
Although variables such as clinical presentation, 
histopathological data and staging are considered to be 
appropriate instruments for evaluating the prognosis of 
melanoma cases, these variables are not always sufficient 
to accurately predict the evolution of a specific case.14 
Patients with similar clinical and anatomic-pathologic 
prognostic factors may progress in different manners, 
sometimes progressing favorably, sometimes with disease 
dissemination, probably because of the intrinsic properties 
of these tumor cells. A number of studies have examined 
molecular factors that may explain such differences, 
particularly focusing on genetic changes involved in 
tumorigenesis and melanoma progression.2, 17- 19
OBJECTIVES
·	 To study the clinical and epidemiologic aspects in pri-
mary skin melanomas. 
·	 To survey histopathological data (Breslow index, Clark 
level, ulceration, mitotic index and regression) revised 
according to the Brazilian Melanoma Group’s protocol.
·	 To correlate these data with primary cutaneous melano-
ma-treated patient evolution.
METHODS
This retrospective study comprises 84 primary cutaneous 
melanoma-diagnosed patients who underwent surgical 
treatment between 1990 and 2007, in private practice (50 
cases) and at the Sistema Unico de Saude (SUS, Unified 
Health System) unit (34 cases).
Clinical, epidemiologic, histological and disease 
evolution data were collected at the pre- and post-operative 
follow-up of study patients. The histological preparations 
were reviewed, and new slides were obtained from paraffin 
blocks when necessary, and stained with hematoxylin and 
eosin (HE), with the prognostic parameters being evaluated 
in compliance with the protocol set by the Brazilian 
Melanoma Group.20
Demographic data (age, sex and ethnicity), topographic 
location and histopathological data (Breslow index, Clark 
level, ulceration, mitotic index, regression and peri- and 
intra-tumor infiltration) were surveyed for the treated cases.
Variables were described in frequencies or means and 
standard deviations, and they were compared with the Chi-
square test, Fisher exact test and Student’s t test. 
The evaluation of disease-free survival and cancer-
specific survival was performed through actuarial analysis, 
and confirmed using the Kaplan-Meier Product.21 In this 
analysis, only melanomas > 1 mm were included. 
For result analysis, the rejection probability of the 95% 
hypothesis (p < 0.05) was adopted.
The study was approved by the Research Ethics 
Committees of the University of Sao Paulo Medical School 
(16/02/2005), A C Camargo Hospital (15/10/2007), and 
Brigadeiro Hospital (05/09/2007).
RESULTS
There were no significant differences of frequency 
between genders (Table 1), (p = 0.1266). Only 1 African-
American patient participated in the study (1%); the 
remaining patients were Caucasian. 
This patient group’s mean age was 54.8+18.1 years, 
which was similar for both genders: 56.0+17.9 for males 
and 53.9+18.4 for females (p = 0.6190), and ranged from 
13-91 years old. In addition, there were no significant age 
differences between genders when they were compared by 
decade of life (p = 0.1942).
Melanomas are predominant in the trunk in males 
(42.8%), and the lower limbs in females (36.7%) (p = 
0.0113). 
There was no evidence of differences between genders 
when the mean ages and standard deviations were assessed 
for the location of lesions. 
Comparing location of the lesions in relation of the 
patient gender there was a significant difference (p = 
0.0113), being lesions in the head and neck and in the trunk 
particularly more frequent in males, while lesions in the 
upper and lower limbs are more frequent in females (Figure 
1).
When analyzing the curves representing mean ages in 
relation to lesion sites in the male group, the following was 
observed: head and neck lesions appeared at significantly 
older ages than lower limb (p < 0.001) and trunk (p < 0.001) 
lesions. Similarly, upper limb lesions affected older males 
significantly more than lower limb (p = 0.014) and trunk (p 
= 0.007) lesions.
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distribution regarding Clark levels (p = 0.461). 
There was no evidence of differences in the tumor 
Breslow index, in terms of mean age (and standard 
deviations); however, there was a wide age range in these 
groups. In addition, no significant differences were observed 
when Clark levels were analyzed with respect to patient age. 
Breslow index frequencies, as distributed according to 
lesion sites, were widely varied. In Figure 2, we observed 
that there was a higher frequency of tumors thicker than 1 
mm (65.2%) in the lower limb lesions, while tumors less 
than 1 mm thick were significantly predominant in trunk 
lesions (p < 0.001).
The Clark level distribution according to tumor location 
demonstrated that level III tumors were predominant in the 
lower and upper limbs and the trunk (p < 0.001), while there 
was no difference in the distribution in the head and neck.
To ensure a minimum 24 months follow-up in patient 
disease-free and overall survival evaluation, melanoma 
diagnosed and treated as of October 2006 were excluded, 
as well as in situ cutaneous melanoma, and predisposing 
disease (xeroderma pigmentosum). 
Of the 54 patients (27 with melanoma > 1 mm and 27 
with melanoma < 1 mm) included in this evaluation, disease 
dissemination was observed in 12 patients (22.2%), of 
which 10 (18.5%) progressed to death, while 2 were still 
on oncological follow-up (3.7%). Disease dissemination 
was not observed in any of the patients with < 1 mm-thick 
melanoma. 
There was no difference of disease dissemination between 
genders (p = 0.577), and was observed in 50% of females and 
53.3% of males. The mean age of patients with disseminated 
disease (60.7+21.1) was not different (p = 0.850) from that 
of patients without relapse (59.3+15.2). In addition, there was 
no difference in the distribution of frequencies relative to the 
melanoma site (p = 0.950).
The differences found in the patient evolution 
analysis in relation to the Breslow indexes (Table 2) were 
Table 1- Clinical and epidemiologic findings in 84 patients 
with primary cutaneous melanoma
Variables Males Females Overall Group
41.7% 58.3%
Age (mean ± stan-
dard deviation)
56.0±17.9 years 53.9±18.4 years 54.8±18.1 years
Decades of life
- up to the 3rd 11.4% 12.2% 11.9%
- 4th 5.7% 16.3% 11.9%
- 5th 14.3% 24.5% 20.2%
- 6th 20.0% 6.2% 11.9%
- 7th 31.5% 16.3% 22.6%
- 8th 11.4% 16.3% 14.3%
- 9th 5.7% 8.2% 7.2%
Lesion site
- Head and neck 31.5% 18.4% 23.2%
- Lower limbs 14.3% 36.7% 27.6%
- Upper limbs 11.4% 24.5% 21.8%
- Trunk 42.8% 20.4% 27.4%
Breslow index
- in situ 11.4% 18.4% 15.5%
- < 1 mm 34.3% 42.8% 39.3%
- 1-2 mm 17.1% 16.3% 16.7%
- 2-4 mm 25.8% 10.3% 16.7%
- > 4 mm 11.4% 12.2% 11.8%
Clark levels 
- I 14.3% 18.4% 16.7%
- II 14.3% 12.2% 13.1%
- III 40.0% 36.7% 38.0%
- IV 31.4% 24.5% 27.4%
- V 0 8.2% 4.8%
Figure 1 - Distribution of frequencies relative to primary cutaneous mela-
noma site
In the female group, head and neck lesions affected older 
patients significantly more than lower limb (p = 0.020) and 
trunk (p = 0.004) lesions; in the remaining locations, there 
were no significant differences. 
Among the morphological parameters, there was 
homogeneous distribution of patients regarding depth 
(Breslow) of lesions, although there was a higher frequency 
of lesions smaller than 1 mm (54.8%). There was uniform 
Figure 2 - Distribution of frequencies relative to Breslow index in accordance 
with primary cutaneous melanoma site
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statistically significant (p = 0.042), revealing that 50% 
of patients with disseminated disease had > 4 mm-thick 
melanomas as compared to 13.3% of patients with no 
disease dissemination. This difference was significant (p = 
0.043) when Breslow index means were compared between 
disseminated (4.6+2.8 mm) and non-disseminated (2.6+2.3 
mm) melanomas.
Ulceration was also significantly associated with 
unfavorable patient evolution, affecting nine out of twelve 
cases with melanoma dissemination (p < 0.001), as seen in 
Table 3. 
The mitotic index was correlated to Breslow index (p 
= 0.0002), as seen in Table 4. The number of mitoses was 
significantly higher in patients with disease progression (p 
= 0.0171), as shown in Table 5. 
A sentinel lymph node biopsy was performed in 19/54 
patients, of which 2 had lymph nodes metastasis. One case 
evolved to dissemination and death, while the other is still 
on clinical follow-up.
Among patients with melanoma dissemination, the mean 
disease-free survival time was 17.8+18.3 months (range, 
4-65 months). The actuarial analysis, as confirmed using the 
Kaplan-Meier Product, revealed an 82% disease-free rate for 
1 year, 70% for 2 years and 62% for 5 years.
Cancer-specific mean survival time was 24.5+20.7 months 
(range, 5-67 months). Survival rates, as calculated by the 
actuarial analysis and Kaplan-Meier Product, revealed an 85% 
survival rate for 1 year, 82% for 2 years and 70% for 5 years.
Table 2 - Percent distribution of frequencies relative to the 
evolution of 27 patients with Breslow index > 1 mm
Breslow index Disseminated disease P value
Absent Present
1-2 mm 9 2
2-4 mm 4 4
> 4 mm 2 6 0.042
Table 3 - Distribution of frequencies relative to the evolution of 54 patients with melanoma according to the presence or 
absence of ulceration
Ulceration
Disseminated disease
Total
Absent Present
N % N % n %
Yes 3 7.1 9 75.0 12 22.2
No 39 92.9 3 25.0 42 77.8
Total 42 100.0 12 100.0 54 100.0
Freedom degree: 1. Calculated chi-square: 28.94. Calculated p value: < 0.001
Table 4 - Distribution of frequencies relative to the number of mitoses per mm2 according to Breslow’s index
Breslow index
Number of mitoses per mm2
Total
Zero > 1
n % n % n %
<1 mm 18 81.8 9 28.1 27 50.0
>1 mm 4 18.2 23 71.9 27 50.0
Total 22 100.0 32 100.0 54 100.0
Fisher exact test. Calculated p value: 0.0002.
Table 5 - Distribution of frequencies relative to the evolution of 54 patients with melanoma according to the number of mitoses per mm2
Number of
mitoses per 
mm2
Disseminated disease Total
Absent Present
n % n % n %
Zero 21 50.0 1 8.3 22 40.7
>1 21 50.0 11 91.7 32 59.3
Total 42 100.0 12 100.0 54 100.0
Fisher exact test. Calculated p value: 0.0171.
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DISCUSSION
Malignant cutaneous melanoma is still a major clinical 
challenge, especially when we take into consideration 
the increasing incidence of smaller lesions that have been 
recorded in the last decades in developed countries,22 and 
more notably, in their Caucasian populations.3 Melanoma is 
still the main cause of death due to skin cancer.14
In the south region of Brazil, the relative increase of 
melanoma incidence between 1979 and 1987 was 38% 
among men and 11% among women.3 Such an increase, 
although in lower proportions, was subsequently confirmed 
in surveys carried out in Sao Paulo between 1963 and 1997, 
23
 and between 1993 and 2006,24 and in Goiania from 1988 
to 2000.25 
These Brazilian data are not different from the results 
of epidemiologic studies conducted in other countries, like 
Scotland (a rise of 303% for men and 187% for women over 
eleven years),13 the United States (increasing incidence of 
cutaneous melanoma),26,27 Queensland, Australia (increasing 
by more than 50% in women and more than doubling in 
men), 28 Sweden (5% annual increase),29 New South Wales, 
Australia (incidence rates are much higher than a few 
decades before),30 Japan (annual increase ratio for deaths 
of 6.3%)31 and British Columbia, Canada (3-7% a year 
frequency increase for new cases, even doubling at each 
10-15 year period, depending on the population studied)32. 
The available diagnostic methods for early detection 
of the disease, based on microscopic findings of the tissue 
morphology, still lack accuracy.1 Likewise, the clinical and 
histological variables determining the disease prognosis 
include the Breslow index, tumor size, presence of 
ulceration, mitotic index and level of vascular invasion, 
but gaps in the definition of risk groups persist, as this 
neoplasm’s clinical manifestation is quite variable from case 
to case.14, 33
From an epidemiological perspective, we noticed that 
this pathology affected men and women equally often 
and at similar mean ages, corroborating the data found in 
the international and national literature.4,22,23,34 Reports of 
differences between genders in the incidence of cutaneous 
melanoma appear to be related to each country’s culture, in 
terms of which part of the body is exposed to the sun more 
often and by whom (Jordan).35 
Among males trunk lesions were more frequent (42.8%), 
while among females the lower limb lesions prevaled 
(36.6%). Such results confirm the relation of cutaneous 
melanoma with solar radiation, as the higher melanoma 
incidence in areas that were more exposed to the sun resulted 
in a disease incidence in different locations in males and 
females, according to their habits and vestments in Brazil. 
These findings are consistent with reports identifying the 
most frequent tumor sites as the backs of males (49.5%), and 
the lower limbs of females (33.1%) in the southern region 
of Brazil.36 Criado et al.23 had even observed a likelihood 
2.26-times as high for males to develop cutaneous melanoma 
in the posterior region of the trunk, while the likelihood for 
the disease to occur on the lower limbs was 2.4-times as 
high in females. 
There was no evidence of differences between genders 
when assessing mean age, Clark level and Breslow index, 
except for lesions having a thickness of 2 to 4 mm, which 
were significantly more frequent in males (p = 0.049). 
The increased incidence currently being reported for this 
neoplasm generally refers to thinner or in situ lesions.13,29 
However in males, an increase in the number of patients with 
thicker lesions has also been demonstrated.16,27
This study identified an 18.5% rate of disease 
dissemination resulting in death, and a 3.7% rate of disease 
dissemination without death. Therefore, 22.2% of patients 
had disease dissemination, with no differences between 
males and females and no influence by patient age or lesion 
site.
Disease dissemination was observed an average of 
17.8 months from lesion diagnosis, and deaths occurred an 
average of 24.5 months from the initial diagnosis. There 
was no correlation between these mean times and lesion 
thickness, suggesting an association of > 1 mm-thick lesion 
dissemination risk with other characteristics. 
The Breslow index constituted a predictive variable of 
disease evolution, as no patient with a < 1 mm-thick tumor 
progressed to disease dissemination, while patients with > 
1 mm-thick tumors had dissemination, particularly those 
with > 4 mm-thick tumors, confirming the reports of other 
publications.4,9,15 
Likewise, the number of detected mitoses in the primary 
tumor may follow the progression of the disease (r = 0.43), 
and it may constitute, along with ulceration and Breslow 
index, the group of associated factors that can best predict 
patient tumor evolution.
Of the 27 > 1 mm melanoma cases used for disease-
free and survival time analysis, 12 had ulcerated lesions, 
and 9 of those 12 lesions had disease dissemination. Of 
the patients with a Breslow index greater than 4 mm, 7 had 
ulceration, and 6 of those 7 ulcerations progressed to death 
or dissemination.
Breslow index association with the presence of ulceration 
and mitotic index showed a clear correlation with patient 
evolution when converted into a numeric score: sum of 
ulceration (0 when absent or 1 when present), Breslow index 
(1 when < 1 mm, 2 when > 1 and < 4 mm, 3 when > 4 mm) 
and mitotic index (0 when absent or 1 when >1 per mm2). 
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The study also identified a 63% disease-free survival 
time rate, and a 70% cancer-specific 5-year survival rate. 
In São Paulo, Brazil, Criado et al.22 reported a similar 
5-year survival (67.4%) to that found in Great Britain by 
Carmichael et al.32 (55.5% for males and 70.3% for females).
CONCLUSIONS
·	 Melanoma is a low-incidence skin tumor that is showing 
an increasing incidence in the last decades.
·	 A higher incidence of melanoma was found in sun-
exposed areas, with trunk lesions being more frequent 
in males, and lower limb lesions being predominant in 
females.
·	 The mean time elapsed from treatment to melanoma dis-
semination diagnosis was 17.8 months.
·	 The survival rates calculated through actuarial analysis 
and the Kaplan-Meier Product revealed a 5-year survival 
rate of seventy percent.
·	 Deeper tumors correlated with more unfavorable patient 
disease evolution, which correlated with the Breslow 
index.
·	 The presence of ulcer and mitotic index had also impact 
in patient disease evolution.
Table 6 - Distribution of frequencies relative to the disease evolution of 54 patients with melanoma in relation to the sum of 
the Breslow index, ulceration and the mitotic index
Indicator*
(Score)
Disseminated disease
Total
Absent Present
n % n % n %
5 1  2.4 6 50.0 7 13.0
4 2  4.8 4 33.3 6 11.1
3 9 21.4 1 33.3 10 18.5
2 11 26.2 1  8.3 12 22.2
1 19 45.2 0  0.0 19 35.2
Total 42 100.0 12 100.0 54 100.0
* Sum of ulceration (0 when absent or 1 when present), Breslow index (1 when < 1 mm, 2 when > 1 and < 4 mm, 3 when > 4 mm) and mitotic index 
(0 when absent or 1 when >1 per mm2)
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